5 Questions for: gene therapy developer Celladon's CEO
This article was originally published in Scrip
Executive Summary
San Diego-based Celladon grossed $50.6m in an initial public offering earlier this year, which will help the company do something that's somewhat unique in gene therapy: target a disease with a fairly large market rather than a monogenic orphan indication.